Frequently Asked Questions

Sometimes we do not know which treatment is best to give patients.  To find out, we compare different treatments by putting patients into groups with each group receiving a different treatment.  To ensure the groups are the same to start with, each patient is put into a group by chance i.e. randomly, selected using a computer that has no personal information about you. 

One group is called the ‘active’ group and will receive Carvedilol and the other group, called the ‘control’ group, will receive a placebo treatment.  There is a one in two chance of being allocated to either treatment (like flipping a coin). 

The placebo treatment is a blank (or dummy) treatment and is made to resemble a Carvedilol tablet. Placebo does not contain any active drug. Using a placebo is called a ‘placebo controlled trial’ and ensures that the trial results are reliable by checking that any effects are actually due to the active drug and not influenced by you or your doctor from what we ‘expect’ to happen. 

Neither you nor the research team nor the medical team will know which treatment you are receiving so this does not influence the trial results. This is called ‘blinding’.  However, should we need to know what treatment you are on, there are mechanisms in place to ‘unblind’ if necessary.

All participants will be followed up at regular 6 month intervals and will have various routine tests. All of the tests in BOPPP are standard as part of your normal medical care when you have liver disease (cirrhosis).

There are two research specific questionnaires that we ask participants to complete: 1) a Quality of Life questionnaire and 2) a Healthcare Use questionnaire.

Trial treatment will be started at a small dose and increased after one week if required. You will be supported by a research nurse through your participation in the trial. This will not include conventional clinical care.

We ask all participants to take the study medication (beta-blocker of placebo) for 3 years in total. This does not stop you from withdrawing at any time and for any reason – without affecting your clinical care at your Hospital.  

You will be asked to take one or two tablets every day.  Neither you nor the research team nor the medical team will know which treatment you are receiving so this does not influence the trial results. This is called ‘blinding’.  However, should we need to know what treatment you are on, there are mechanisms in place to ‘unblind’ if necessary.

Every 6 months, you will be seen at your hospital by your usual Consultant team as part of routine clinical care and have the usual range of tests that you would have normally. There are no extra research tests in this trial. During the same visit, you will also be seen by a Research Nurse who will ask you to complete 2 research questionnaires. Your study medication will be given to you at this visit. 

Sometimes we do not know which treatment is best to give patients.  To find out, we compare different treatments by putting patients into groups with each group receiving a different treatment.  To ensure the groups are the same to start with, each patient is put into a group by chance i.e. randomly, selected using a computer that has no personal information about you. 

One group is called the ‘active’ group and will receive Carvedilol and the other group, called the ‘control’ group, will receive a placebo treatment.  There is a one in two chance of being allocated to either treatment (like flipping a coin). 

The placebo treatment is a blank (or dummy) treatment and is made to resemble a Carvedilol tablet. Placebo does not contain any active drug. Using a placebo is called a ‘placebo controlled trial’ and ensures that the trial results are reliable by checking that any effects are actually due to the active drug and not influenced by you or your doctor from what we ‘expect’ to happen. 

Neither you nor the research team nor the medical team will know which treatment you are receiving so this does not influence the trial results. This is called ‘blinding’.  However, should we need to know what treatment you are on, there are mechanisms in place to ‘unblind’ if necessary.

All participants will be followed up at regular 6 month intervals and will have various routine tests. All of the tests in BOPPP are standard as part of your normal medical care when you have liver disease (cirrhosis).

There are two research specific questionnaires that we ask participants to complete: 1) a Quality of Life questionnaire and 2) a Healthcare Use questionnaire.

Trial treatment will be started at a small dose and increased after one week if required. You will be supported by a research nurse through your participation in the trial. This will not include conventional clinical care.

We ask all participants to take the study medication (beta-blocker of placebo) for 3 years in total. This does not stop you from withdrawing at any time and for any reason – without affecting your clinical care at your Hospital.  

You will be asked to take one or two tablets every day.  Neither you nor the research team nor the medical team will know which treatment you are receiving so this does not influence the trial results. This is called ‘blinding’.  However, should we need to know what treatment you are on, there are mechanisms in place to ‘unblind’ if necessary.

Every 6 months, you will be seen at your hospital by your usual Consultant team as part of routine clinical care and have the usual range of tests that you would have normally. There are no extra research tests in this trial. During the same visit, you will also be seen by a Research Nurse who will ask you to complete 2 research questionnaires. Your study medication will be given to you at this visit. 

Sometimes we do not know which treatment is best to give patients.  To find out, we compare different treatments by putting patients into groups with each group receiving a different treatment.  To ensure the groups are the same to start with, each patient is put into a group by chance i.e. randomly, selected using a computer that has no personal information about you. 

One group is called the ‘active’ group and will receive Carvedilol and the other group, called the ‘control’ group, will receive a placebo treatment.  There is a one in two chance of being allocated to either treatment (like flipping a coin). 

The placebo treatment is a blank (or dummy) treatment and is made to resemble a Carvedilol tablet. Placebo does not contain any active drug. Using a placebo is called a ‘placebo controlled trial’ and ensures that the trial results are reliable by checking that any effects are actually due to the active drug and not influenced by you or your doctor from what we ‘expect’ to happen. 

Neither you nor the research team nor the medical team will know which treatment you are receiving so this does not influence the trial results. This is called ‘blinding’.  However, should we need to know what treatment you are on, there are mechanisms in place to ‘unblind’ if necessary.

All participants will be followed up at regular 6 month intervals and will have various routine tests. All of the tests in BOPPP are standard as part of your normal medical care when you have liver disease (cirrhosis).

There are two research specific questionnaires that we ask participants to complete: 1) a Quality of Life questionnaire and 2) a Healthcare Use questionnaire.

Trial treatment will be started at a small dose and increased after one week if required. You will be supported by a research nurse through your participation in the trial. This will not include conventional clinical care.

We ask all participants to take the study medication (beta-blocker of placebo) for 3 years in total. This does not stop you from withdrawing at any time and for any reason – without affecting your clinical care at your Hospital.  

You will be asked to take one or two tablets every day.  Neither you nor the research team nor the medical team will know which treatment you are receiving so this does not influence the trial results. This is called ‘blinding’.  However, should we need to know what treatment you are on, there are mechanisms in place to ‘unblind’ if necessary.

Every 6 months, you will be seen at your hospital by your usual Consultant team as part of routine clinical care and have the usual range of tests that you would have normally. There are no extra research tests in this trial. During the same visit, you will also be seen by a Research Nurse who will ask you to complete 2 research questionnaires. Your study medication will be given to you at this visit. 

Sometimes we do not know which treatment is best to give patients.  To find out, we compare different treatments by putting patients into groups with each group receiving a different treatment.  To ensure the groups are the same to start with, each patient is put into a group by chance i.e. randomly, selected using a computer that has no personal information about you. 

One group is called the ‘active’ group and will receive Carvedilol and the other group, called the ‘control’ group, will receive a placebo treatment.  There is a one in two chance of being allocated to either treatment (like flipping a coin). 

The placebo treatment is a blank (or dummy) treatment and is made to resemble a Carvedilol tablet. Placebo does not contain any active drug. Using a placebo is called a ‘placebo controlled trial’ and ensures that the trial results are reliable by checking that any effects are actually due to the active drug and not influenced by you or your doctor from what we ‘expect’ to happen. 

Neither you nor the research team nor the medical team will know which treatment you are receiving so this does not influence the trial results. This is called ‘blinding’.  However, should we need to know what treatment you are on, there are mechanisms in place to ‘unblind’ if necessary.

All participants will be followed up at regular 6 month intervals and will have various routine tests. All of the tests in BOPPP are standard as part of your normal medical care when you have liver disease (cirrhosis).

There are two research specific questionnaires that we ask participants to complete: 1) a Quality of Life questionnaire and 2) a Healthcare Use questionnaire.

Trial treatment will be started at a small dose and increased after one week if required. You will be supported by a research nurse through your participation in the trial. This will not include conventional clinical care.

We ask all participants to take the study medication (beta-blocker of placebo) for 3 years in total. This does not stop you from withdrawing at any time and for any reason – without affecting your clinical care at your Hospital.  

You will be asked to take one or two tablets every day.  Neither you nor the research team nor the medical team will know which treatment you are receiving so this does not influence the trial results. This is called ‘blinding’.  However, should we need to know what treatment you are on, there are mechanisms in place to ‘unblind’ if necessary.

Every 6 months, you will be seen at your hospital by your usual Consultant team as part of routine clinical care and have the usual range of tests that you would have normally. There are no extra research tests in this trial. During the same visit, you will also be seen by a Research Nurse who will ask you to complete 2 research questionnaires. Your study medication will be given to you at this visit. 

Sometimes we do not know which treatment is best to give patients.  To find out, we compare different treatments by putting patients into groups with each group receiving a different treatment.  To ensure the groups are the same to start with, each patient is put into a group by chance i.e. randomly, selected using a computer that has no personal information about you. 

One group is called the ‘active’ group and will receive Carvedilol and the other group, called the ‘control’ group, will receive a placebo treatment.  There is a one in two chance of being allocated to either treatment (like flipping a coin). 

The placebo treatment is a blank (or dummy) treatment and is made to resemble a Carvedilol tablet. Placebo does not contain any active drug. Using a placebo is called a ‘placebo controlled trial’ and ensures that the trial results are reliable by checking that any effects are actually due to the active drug and not influenced by you or your doctor from what we ‘expect’ to happen. 

Neither you nor the research team nor the medical team will know which treatment you are receiving so this does not influence the trial results. This is called ‘blinding’.  However, should we need to know what treatment you are on, there are mechanisms in place to ‘unblind’ if necessary.

All participants will be followed up at regular 6 month intervals and will have various routine tests. All of the tests in BOPPP are standard as part of your normal medical care when you have liver disease (cirrhosis).

There are two research specific questionnaires that we ask participants to complete: 1) a Quality of Life questionnaire and 2) a Healthcare Use questionnaire.

Trial treatment will be started at a small dose and increased after one week if required. You will be supported by a research nurse through your participation in the trial. This will not include conventional clinical care.

We ask all participants to take the study medication (beta-blocker of placebo) for 3 years in total. This does not stop you from withdrawing at any time and for any reason – without affecting your clinical care at your Hospital.  

You will be asked to take one or two tablets every day.  Neither you nor the research team nor the medical team will know which treatment you are receiving so this does not influence the trial results. This is called ‘blinding’.  However, should we need to know what treatment you are on, there are mechanisms in place to ‘unblind’ if necessary.

Every 6 months, you will be seen at your hospital by your usual Consultant team as part of routine clinical care and have the usual range of tests that you would have normally. There are no extra research tests in this trial. During the same visit, you will also be seen by a Research Nurse who will ask you to complete 2 research questionnaires. Your study medication will be given to you at this visit. 

Sometimes we do not know which treatment is best to give patients.  To find out, we compare different treatments by putting patients into groups with each group receiving a different treatment.  To ensure the groups are the same to start with, each patient is put into a group by chance i.e. randomly, selected using a computer that has no personal information about you. 

One group is called the ‘active’ group and will receive Carvedilol and the other group, called the ‘control’ group, will receive a placebo treatment.  There is a one in two chance of being allocated to either treatment (like flipping a coin). 

The placebo treatment is a blank (or dummy) treatment and is made to resemble a Carvedilol tablet. Placebo does not contain any active drug. Using a placebo is called a ‘placebo controlled trial’ and ensures that the trial results are reliable by checking that any effects are actually due to the active drug and not influenced by you or your doctor from what we ‘expect’ to happen. 

Neither you nor the research team nor the medical team will know which treatment you are receiving so this does not influence the trial results. This is called ‘blinding’.  However, should we need to know what treatment you are on, there are mechanisms in place to ‘unblind’ if necessary.

All participants will be followed up at regular 6 month intervals and will have various routine tests. All of the tests in BOPPP are standard as part of your normal medical care when you have liver disease (cirrhosis).

There are two research specific questionnaires that we ask participants to complete: 1) a Quality of Life questionnaire and 2) a Healthcare Use questionnaire.

Trial treatment will be started at a small dose and increased after one week if required. You will be supported by a research nurse through your participation in the trial. This will not include conventional clinical care.

We ask all participants to take the study medication (beta-blocker of placebo) for 3 years in total. This does not stop you from withdrawing at any time and for any reason – without affecting your clinical care at your Hospital.  

You will be asked to take one or two tablets every day.  Neither you nor the research team nor the medical team will know which treatment you are receiving so this does not influence the trial results. This is called ‘blinding’.  However, should we need to know what treatment you are on, there are mechanisms in place to ‘unblind’ if necessary.

Every 6 months, you will be seen at your hospital by your usual Consultant team as part of routine clinical care and have the usual range of tests that you would have normally. There are no extra research tests in this trial. During the same visit, you will also be seen by a Research Nurse who will ask you to complete 2 research questionnaires. Your study medication will be given to you at this visit. 

Sometimes we do not know which treatment is best to give patients.  To find out, we compare different treatments by putting patients into groups with each group receiving a different treatment.  To ensure the groups are the same to start with, each patient is put into a group by chance i.e. randomly, selected using a computer that has no personal information about you. 

One group is called the ‘active’ group and will receive Carvedilol and the other group, called the ‘control’ group, will receive a placebo treatment.  There is a one in two chance of being allocated to either treatment (like flipping a coin). 

The placebo treatment is a blank (or dummy) treatment and is made to resemble a Carvedilol tablet. Placebo does not contain any active drug. Using a placebo is called a ‘placebo controlled trial’ and ensures that the trial results are reliable by checking that any effects are actually due to the active drug and not influenced by you or your doctor from what we ‘expect’ to happen. 

Neither you nor the research team nor the medical team will know which treatment you are receiving so this does not influence the trial results. This is called ‘blinding’.  However, should we need to know what treatment you are on, there are mechanisms in place to ‘unblind’ if necessary.

All participants will be followed up at regular 6 month intervals and will have various routine tests. All of the tests in BOPPP are standard as part of your normal medical care when you have liver disease (cirrhosis).

There are two research specific questionnaires that we ask participants to complete: 1) a Quality of Life questionnaire and 2) a Healthcare Use questionnaire.

Trial treatment will be started at a small dose and increased after one week if required. You will be supported by a research nurse through your participation in the trial. This will not include conventional clinical care.

We ask all participants to take the study medication (beta-blocker of placebo) for 3 years in total. This does not stop you from withdrawing at any time and for any reason – without affecting your clinical care at your Hospital.  

You will be asked to take one or two tablets every day.  Neither you nor the research team nor the medical team will know which treatment you are receiving so this does not influence the trial results. This is called ‘blinding’.  However, should we need to know what treatment you are on, there are mechanisms in place to ‘unblind’ if necessary.

Every 6 months, you will be seen at your hospital by your usual Consultant team as part of routine clinical care and have the usual range of tests that you would have normally. There are no extra research tests in this trial. During the same visit, you will also be seen by a Research Nurse who will ask you to complete 2 research questionnaires. Your study medication will be given to you at this visit. 

Sometimes we do not know which treatment is best to give patients.  To find out, we compare different treatments by putting patients into groups with each group receiving a different treatment.  To ensure the groups are the same to start with, each patient is put into a group by chance i.e. randomly, selected using a computer that has no personal information about you. 

One group is called the ‘active’ group and will receive Carvedilol and the other group, called the ‘control’ group, will receive a placebo treatment.  There is a one in two chance of being allocated to either treatment (like flipping a coin). 

The placebo treatment is a blank (or dummy) treatment and is made to resemble a Carvedilol tablet. Placebo does not contain any active drug. Using a placebo is called a ‘placebo controlled trial’ and ensures that the trial results are reliable by checking that any effects are actually due to the active drug and not influenced by you or your doctor from what we ‘expect’ to happen. 

Neither you nor the research team nor the medical team will know which treatment you are receiving so this does not influence the trial results. This is called ‘blinding’.  However, should we need to know what treatment you are on, there are mechanisms in place to ‘unblind’ if necessary.

All participants will be followed up at regular 6 month intervals and will have various routine tests. All of the tests in BOPPP are standard as part of your normal medical care when you have liver disease (cirrhosis).

There are two research specific questionnaires that we ask participants to complete: 1) a Quality of Life questionnaire and 2) a Healthcare Use questionnaire.

Trial treatment will be started at a small dose and increased after one week if required. You will be supported by a research nurse through your participation in the trial. This will not include conventional clinical care.

We ask all participants to take the study medication (beta-blocker of placebo) for 3 years in total. This does not stop you from withdrawing at any time and for any reason – without affecting your clinical care at your Hospital.  

You will be asked to take one or two tablets every day.  Neither you nor the research team nor the medical team will know which treatment you are receiving so this does not influence the trial results. This is called ‘blinding’.  However, should we need to know what treatment you are on, there are mechanisms in place to ‘unblind’ if necessary.

Every 6 months, you will be seen at your hospital by your usual Consultant team as part of routine clinical care and have the usual range of tests that you would have normally. There are no extra research tests in this trial. During the same visit, you will also be seen by a Research Nurse who will ask you to complete 2 research questionnaires. Your study medication will be given to you at this visit. 

Sometimes we do not know which treatment is best to give patients.  To find out, we compare different treatments by putting patients into groups with each group receiving a different treatment.  To ensure the groups are the same to start with, each patient is put into a group by chance i.e. randomly, selected using a computer that has no personal information about you. 

One group is called the ‘active’ group and will receive Carvedilol and the other group, called the ‘control’ group, will receive a placebo treatment.  There is a one in two chance of being allocated to either treatment (like flipping a coin). 

The placebo treatment is a blank (or dummy) treatment and is made to resemble a Carvedilol tablet. Placebo does not contain any active drug. Using a placebo is called a ‘placebo controlled trial’ and ensures that the trial results are reliable by checking that any effects are actually due to the active drug and not influenced by you or your doctor from what we ‘expect’ to happen. 

Neither you nor the research team nor the medical team will know which treatment you are receiving so this does not influence the trial results. This is called ‘blinding’.  However, should we need to know what treatment you are on, there are mechanisms in place to ‘unblind’ if necessary.

All participants will be followed up at regular 6 month intervals and will have various routine tests. All of the tests in BOPPP are standard as part of your normal medical care when you have liver disease (cirrhosis).

There are two research specific questionnaires that we ask participants to complete: 1) a Quality of Life questionnaire and 2) a Healthcare Use questionnaire.

Trial treatment will be started at a small dose and increased after one week if required. You will be supported by a research nurse through your participation in the trial. This will not include conventional clinical care.

We ask all participants to take the study medication (beta-blocker of placebo) for 3 years in total. This does not stop you from withdrawing at any time and for any reason – without affecting your clinical care at your Hospital.  

You will be asked to take one or two tablets every day.  Neither you nor the research team nor the medical team will know which treatment you are receiving so this does not influence the trial results. This is called ‘blinding’.  However, should we need to know what treatment you are on, there are mechanisms in place to ‘unblind’ if necessary.

Every 6 months, you will be seen at your hospital by your usual Consultant team as part of routine clinical care and have the usual range of tests that you would have normally. There are no extra research tests in this trial. During the same visit, you will also be seen by a Research Nurse who will ask you to complete 2 research questionnaires. Your study medication will be given to you at this visit. 

Sometimes we do not know which treatment is best to give patients.  To find out, we compare different treatments by putting patients into groups with each group receiving a different treatment.  To ensure the groups are the same to start with, each patient is put into a group by chance i.e. randomly, selected using a computer that has no personal information about you. 

One group is called the ‘active’ group and will receive Carvedilol and the other group, called the ‘control’ group, will receive a placebo treatment.  There is a one in two chance of being allocated to either treatment (like flipping a coin). 

The placebo treatment is a blank (or dummy) treatment and is made to resemble a Carvedilol tablet. Placebo does not contain any active drug. Using a placebo is called a ‘placebo controlled trial’ and ensures that the trial results are reliable by checking that any effects are actually due to the active drug and not influenced by you or your doctor from what we ‘expect’ to happen. 

Neither you nor the research team nor the medical team will know which treatment you are receiving so this does not influence the trial results. This is called ‘blinding’.  However, should we need to know what treatment you are on, there are mechanisms in place to ‘unblind’ if necessary.

All participants will be followed up at regular 6 month intervals and will have various routine tests. All of the tests in BOPPP are standard as part of your normal medical care when you have liver disease (cirrhosis).

There are two research specific questionnaires that we ask participants to complete: 1) a Quality of Life questionnaire and 2) a Healthcare Use questionnaire.

Trial treatment will be started at a small dose and increased after one week if required. You will be supported by a research nurse through your participation in the trial. This will not include conventional clinical care.

We ask all participants to take the study medication (beta-blocker of placebo) for 3 years in total. This does not stop you from withdrawing at any time and for any reason – without affecting your clinical care at your Hospital.  

You will be asked to take one or two tablets every day.  Neither you nor the research team nor the medical team will know which treatment you are receiving so this does not influence the trial results. This is called ‘blinding’.  However, should we need to know what treatment you are on, there are mechanisms in place to ‘unblind’ if necessary.

Every 6 months, you will be seen at your hospital by your usual Consultant team as part of routine clinical care and have the usual range of tests that you would have normally. There are no extra research tests in this trial. During the same visit, you will also be seen by a Research Nurse who will ask you to complete 2 research questionnaires. Your study medication will be given to you at this visit. 

Sometimes we do not know which treatment is best to give patients.  To find out, we compare different treatments by putting patients into groups with each group receiving a different treatment.  To ensure the groups are the same to start with, each patient is put into a group by chance i.e. randomly, selected using a computer that has no personal information about you. 

One group is called the ‘active’ group and will receive Carvedilol and the other group, called the ‘control’ group, will receive a placebo treatment.  There is a one in two chance of being allocated to either treatment (like flipping a coin). 

The placebo treatment is a blank (or dummy) treatment and is made to resemble a Carvedilol tablet. Placebo does not contain any active drug. Using a placebo is called a ‘placebo controlled trial’ and ensures that the trial results are reliable by checking that any effects are actually due to the active drug and not influenced by you or your doctor from what we ‘expect’ to happen. 

Neither you nor the research team nor the medical team will know which treatment you are receiving so this does not influence the trial results. This is called ‘blinding’.  However, should we need to know what treatment you are on, there are mechanisms in place to ‘unblind’ if necessary.

All participants will be followed up at regular 6 month intervals and will have various routine tests. All of the tests in BOPPP are standard as part of your normal medical care when you have liver disease (cirrhosis).

There are two research specific questionnaires that we ask participants to complete: 1) a Quality of Life questionnaire and 2) a Healthcare Use questionnaire.

Trial treatment will be started at a small dose and increased after one week if required. You will be supported by a research nurse through your participation in the trial. This will not include conventional clinical care.

We ask all participants to take the study medication (beta-blocker of placebo) for 3 years in total. This does not stop you from withdrawing at any time and for any reason – without affecting your clinical care at your Hospital.  

You will be asked to take one or two tablets every day.  Neither you nor the research team nor the medical team will know which treatment you are receiving so this does not influence the trial results. This is called ‘blinding’.  However, should we need to know what treatment you are on, there are mechanisms in place to ‘unblind’ if necessary.

Every 6 months, you will be seen at your hospital by your usual Consultant team as part of routine clinical care and have the usual range of tests that you would have normally. There are no extra research tests in this trial. During the same visit, you will also be seen by a Research Nurse who will ask you to complete 2 research questionnaires. Your study medication will be given to you at this visit. 

Sometimes we do not know which treatment is best to give patients.  To find out, we compare different treatments by putting patients into groups with each group receiving a different treatment.  To ensure the groups are the same to start with, each patient is put into a group by chance i.e. randomly, selected using a computer that has no personal information about you. 

One group is called the ‘active’ group and will receive Carvedilol and the other group, called the ‘control’ group, will receive a placebo treatment.  There is a one in two chance of being allocated to either treatment (like flipping a coin). 

The placebo treatment is a blank (or dummy) treatment and is made to resemble a Carvedilol tablet. Placebo does not contain any active drug. Using a placebo is called a ‘placebo controlled trial’ and ensures that the trial results are reliable by checking that any effects are actually due to the active drug and not influenced by you or your doctor from what we ‘expect’ to happen. 

Neither you nor the research team nor the medical team will know which treatment you are receiving so this does not influence the trial results. This is called ‘blinding’.  However, should we need to know what treatment you are on, there are mechanisms in place to ‘unblind’ if necessary.

All participants will be followed up at regular 6 month intervals and will have various routine tests. All of the tests in BOPPP are standard as part of your normal medical care when you have liver disease (cirrhosis).

There are two research specific questionnaires that we ask participants to complete: 1) a Quality of Life questionnaire and 2) a Healthcare Use questionnaire.

Trial treatment will be started at a small dose and increased after one week if required. You will be supported by a research nurse through your participation in the trial. This will not include conventional clinical care.

We ask all participants to take the study medication (beta-blocker of placebo) for 3 years in total. This does not stop you from withdrawing at any time and for any reason – without affecting your clinical care at your Hospital.  

You will be asked to take one or two tablets every day.  Neither you nor the research team nor the medical team will know which treatment you are receiving so this does not influence the trial results. This is called ‘blinding’.  However, should we need to know what treatment you are on, there are mechanisms in place to ‘unblind’ if necessary.

Every 6 months, you will be seen at your hospital by your usual Consultant team as part of routine clinical care and have the usual range of tests that you would have normally. There are no extra research tests in this trial. During the same visit, you will also be seen by a Research Nurse who will ask you to complete 2 research questionnaires. Your study medication will be given to you at this visit.